Capricor Therapeutics (NASDAQ:CAPR) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) to a strong-buy rating in a research report sent to investors on Thursday morning,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research note on Friday, May 15th. B. Riley Financial raised their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.30.

Capricor Therapeutics Stock Down 13.0%

Shares of NASDAQ CAPR opened at $26.44 on Thursday. The company has a market capitalization of $1.53 billion, a PE ratio of -11.40 and a beta of 0.39. The firm has a fifty day simple moving average of $30.00 and a 200 day simple moving average of $28.41. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities analysts expect that Capricor Therapeutics will post -0.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. This trade represents a 75.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 173,429 shares of company stock worth $5,329,440. 9.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC purchased a new position in Capricor Therapeutics in the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at approximately $49,062,000. RA Capital Management L.P. bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $43,516,000. Finally, Geode Capital Management LLC raised its position in shares of Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock valued at $29,367,000 after buying an additional 55,766 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.